key: cord-0719940-dgczu7ir
authors: Gray, Kathryn J.
title: Maternal COVID-19 vaccine antibody response and passage into cord blood
date: 2021-08-23
journal: J Pediatr
DOI: 10.1016/j.jpeds.2021.06.055
sha: 78a3a4b6706ab0509a283776b98f5316ba14541c
doc_id: 719940
cord_uid: dgczu7ir

nan

tested for superiority over the current treatment. IIT analyzes what was randomized, whether or not patients in the treatment arm used the treatment, and tends to mirror what is likely to occur in practice, where patients may or may not take treatment prescribed. ITT biases results toward equivalence between the 2 groups, which may be desirable when testing a new treatment for superiority. PP, analyzing only patients who were adequately compliant, biases results away from equivalence between the 2 groups (in the case of a medication, the underlying assumption is that a higher dose/longer duration/broader coverage is superior). PP as the primary analysis may be seen below in the Pernica et al non-inferiority study.

-Jordan Hupert, MD Steroid bursts associated with severe adverse events Yao Question What is the association of severe adverse events with a recent corticosteroid burst? Design Self-controlled cohort study (each participant serves as his or her own control before the steroid burst) employing the National Health Insurance Research Database in Taiwan Commentary The authors should be commended for using a self-controlled case series (SCCS) design to control unmeasured and time-invariant confounders. 1 However, the robustness would be strengthened if the key assumptions of SCCS studies were reassurred. 2,3 For example, this study lacked analyses illustrating that "an event does not increase probability of death" and "recurrences of an event are independent." The codes for identifying outcomes could be improved to mitigate misclassification bias. The absolute risk for adverse events was very low, with one additional GI bleeding event occurring among every 1284 steroid bursts, one additional sepsis among every 400 000 bursts, and one additional pneumonia event among every 1284 bursts. Nevertheless, steroid bursts should not be prescribed for indications lacking solid evidence, such as upper respiratory tract infections, in this vulnerable population. Design Randomized, controlled non-inferiority trial.

Setting Two emergency departments (EDs) in Canada.

Participants Six months to 10 years old with chest radiograph confirmed CAP, not requiring hospitalization.

Intervention Five days (+ 5 days placebo) vs 10 days highdose amoxicillin.

Outcomes Clinical cure at 14 to 21 days.

Main Results Twenty-nine of 281 randomized patients (10.3%) were lost to follow-up. Non-inferiority was set at 7.5% (80% power). In per-protocol analysis, 101 of 114 children (88.6%) in the 5-day amoxicillin group and in 99 of 109 (90.8%) in the 10-day amoxicillin group demonstrated clinical cure, risk difference, 0.016 (97.5% CI lower limit, À0.087). In intention-to-treat analysis, 108 of 126 (85.7%) in the 5-day amoxicillin group and in 106 of 126 (84.1%) in the 10-day group demonstrated clinical cure, risk difference 0.023 (97.5% CI lower limit, À0.061).

Conclusions Non-inferiority was achieved by intention-totreat analysis, not by per-protocol analysis (the primary analysis).

Commentary Pernica et al conducted a randomized prospective study comparing clinical cure rates of 5 vs 10 days of oral high-dose amoxicillin therapy. There was no significant difference in cure rates noted (89% in the 5-day group vs 91% in the 10-day group). The authors concluded that short-course is of comparable efficacy vs longer duration antibiotic therapy in resolving pediatric CAP. A methodologic limitation is inclusion of nearly 30% with discrepant CAP radiographic diagnosis of pneumonia between ED physician and radiologist. Also, in a study comparing antibiotic efficacy in resolving CAP, is the difficulty in distinguishing viral vs bacterial infectious etiology (fully one-half of study patients had nasopharyngeal secretion viral isolation). The character of the infiltrate, which can sometimes indicate likely infectious etiology (interstitial vs lobar pattern), was not specified. Such limitations in distinguishing CAP etiology can confound determining whether antibiotic therapy duration truly affected clinical outcome. Question What is the timing of maternal antibody response and passage to the baby (cord blood)?

Design Case series.

Setting New York-Presbyterian Hospital/Weill Cornell Medical Center, New York.

Participants 122 pregnant women with cord blood available at the time of birth who reported receiving 1 or both mRNAbased COVID-19 vaccines and gave birth to a singleton neonate.

Intervention Semi-quantitative testing for antibodies against S-receptor binding domain was performed on leftover clinical sera of maternal peripheral blood to identify antibodies mounted against the vaccine, but who tested negative for antibodies against the nucleocapsid protein antigen (found following COVID-19 infection).

Outcomes Passive COVID-19 antibodies.

Main Results By the time of delivery, 55 pregnant women had received 1 dose of an mRNA vaccine and 67 had received both vaccine doses. All women (who were at least 4 weeks after vaccine dose 1) and cord blood samples, except for 1, had detectable IgG antibodies. 54% and 99% of cord blood samples had detectable IgG from women who received only 1 vaccine dose vs both vaccine doses, respectively. The earliest maternal and cord-blood IgG detection was 5 days and 16 days after the first dose, respectively, and increased over the following number of weeks.

Conclusions These results shed light on possible vaccination strategies for pregnant women.

Commentary When mRNA COVID-19 vaccines received emergency use authorization, no studies had been conducted in pregnancy. This important study by Prabhu et al was one of the first to delineate the effects of vaccine timing on maternal and neonatal SARS-CoV-2 IgG levels. Although maternal and neonatal IgG can be detected as early as 1-2 weeks following vaccine dose 1, more than one-half of neonates do not have detectable IgG until after maternal vaccine dose 2 and titers continue to increase with time since maternal vaccination. Thus, to optimize neonatal immune protection, both vaccine doses should be administered in pregnancy prior to delivery. As study participants were all in the 3rd trimester at the time of vaccination, further data are needed to understand the effects of vaccine administration earlier in pregnancy on placenta-mediated IgG transfer to the neonate. Taken together with other recent work on COVID-19 vaccination in pregnancy, 1,2 as well as the CDC VSafe Pregnancy Registry data, 3 substantial evidence is now available on the efficacy and safety of the mRNA COVID-19 vaccines in pregnancy. Given that both pregnant individuals and neonates are at higher risk for severe COVID-19, vaccination is an important tool for protection of these vulnerable populations. Question What are the predictors for multiple emergency department (ED) visits prior to Kawasaki disease diagnosis? Design Retrospective cohort study.

Setting Boston Children's Hospital ED.

Participants All patients presenting between January 2006 and August 2018 with an eventual diagnosis of Kawasaki disease.

Intervention Logistic regression and regression tree analysis.

Main Results Among 530 patients eventually diagnosed with Kawasaki disease, predictors of >1 ED visit prior to diagnosis included £2 Kawasaki disease criteria, OR 33.9 (95% CI, 18.1-63.6), <3 days of fever at the first visit, OR 3.47 (95% CI, 1.77-6.84), and non-White race, OR 2.15 (95% CI, 1.18-3.95). There were no significant clinical outcomes between patients diagnosed at first ED visit compared with those with multiple visits.

Conclusions Incomplete criteria, fewer days of fever, and non-White race predicted multiple ED visits.

Commentary The diagnosis of Kawasaki disease remains elusive, given its rarity and reliance on clinical criteria without a confirmatory test. Delayed diagnosis increases the likelihood of important coronary artery complications; early diagnosis may be associated with an increased likelihood of non-response to initial treatment. 1 This retrospective, single-institution cohort study noted that an important proportion of patients had repeated emergency room visits before their diagnosis, mostly early in their disease evolution with fewer days of fever and fewer clinical criteria. Fortunately, this did not appear to result in a delay in diagnosis or adverse outcomes. Although non-White race/ethnicity was associated with a greater number of visits, it could not be explained by socioeconomic status or access to care. Increased distance from the clinical center was associated with fewer visits, and previous studies have linked this to delayed diagnosis. 2 This study suggests that the relationship between health behaviors, possible implicit clinical bias, and disparities may be complex. Main Results Among 3206 children/youths (50% male; 26% non-Hispanic White, 35% Mexican American, 39% non-Hispanic Black), adjusting BMI for pubertal stage, reduced the overall percent overweight for boys from 28.6 (24.8-32.6) to 20.8 (17.4-24.7), for girls from 29.0 (25.4-32.8) to 16.9 (13.9-20.1), and obese for boys 14.1 (11.3-17.3) to 6.7 (4.5-9.4), for girls 11.3 (9.0-14.0) to 4.9 (3.3-6.5), respectively. Effects were larger among non-Hispanic Black and Mexican American children compared with non-Hispanic White children.

Conclusions Pubertal adjustment decreased the prevalence of children/youths defined as overweight and obese.

Commentary Bomberg et al provide clinical context to the old and lame joke, "What weighs more, a pound of muscle or a pound of fat?" They show that pubertal status has an impact on obesity classification. In fact, accounting for pubertal status reduces the prevalence of overweight and obesity, based on BMI. The major limitation of using BMI as a marker for obesity is that a pound of muscle and a pound of fat actually weigh the same. Pubertal hormones alter body composition in ways that make BMI more problematic as a measure of obesity. Data from this study were collected from 1988-1994, at the onset of the obesity epidemic, so no solace should be sought regarding the current seriousness of the pediatric obesity problem in the United States from these observations. The impact of this finding on practice falls more into the realm of common sense than science. Central obesity creates the metabolic problem. Therefore, after looking at the BMI classification, check the pubertal status and the waist circumference of your patient. Prepubertal children can be chubbier, but no child should have a beer belly.

Samuel S. Gidding, MD Genomic Medicine Institute, Geisinger, Danville, Pennsylvania

Association of oral corticosteroid bursts with severe adverse events in children

Self-controlled case series methods: an alternative to standard epidemiological study designs

Oral corticosteroid bursts and severe adverse events: a critical appraisal

COVID-19 vaccine response in pregnant and lactating women: a cohort study

Cord blood antibodies following maternal COVID-19 vaccination during pregnancy

CDC v-safe COVID-19 Pregnancy Registry Team. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons

Prediction of intravenous immunoglobulin unreponsiveness in patients with Kawasaki disease

Delayed diagnosis of Kawasaki disease: what are the risk factors?

Adjusting for Pubertal Status Reduces Overweight and Obesity Prevalence in the United States